JP2002539170A - 癌治療における免疫刺激性の細菌膜フラクション - Google Patents
癌治療における免疫刺激性の細菌膜フラクションInfo
- Publication number
- JP2002539170A JP2002539170A JP2000604865A JP2000604865A JP2002539170A JP 2002539170 A JP2002539170 A JP 2002539170A JP 2000604865 A JP2000604865 A JP 2000604865A JP 2000604865 A JP2000604865 A JP 2000604865A JP 2002539170 A JP2002539170 A JP 2002539170A
- Authority
- JP
- Japan
- Prior art keywords
- membrane fraction
- use according
- membrane
- bacteria
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 94
- 230000003308 immunostimulating effect Effects 0.000 title claims description 26
- 206010028980 Neoplasm Diseases 0.000 title claims description 11
- 230000001580 bacterial effect Effects 0.000 title claims description 10
- 201000011510 cancer Diseases 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title claims description 6
- 241000894006 Bacteria Species 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 241000588747 Klebsiella pneumoniae Species 0.000 claims abstract description 12
- 230000001093 anti-cancer Effects 0.000 claims abstract description 9
- 239000008188 pellet Substances 0.000 claims description 52
- 239000000725 suspension Substances 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000005975 antitumor immune response Effects 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 238000005119 centrifugation Methods 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000011394 anticancer treatment Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 8
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 7
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 7
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000002101 lytic effect Effects 0.000 claims description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 2
- 241000588748 Klebsiella Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 27
- 238000004519 manufacturing process Methods 0.000 description 15
- 210000001616 monocyte Anatomy 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 11
- 108010065805 Interleukin-12 Proteins 0.000 description 9
- 102000013462 Interleukin-12 Human genes 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 4
- 108090000317 Chymotrypsin Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101001032334 Homo sapiens Immunity-related GTPase family M protein Proteins 0.000 description 3
- 102100038249 Immunity-related GTPase family M protein Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 101001032335 Mus musculus Immunity-related GTPase family M protein 1 Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229960002376 chymotrypsin Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229950000550 sodium metrizoate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9903154A FR2790960B1 (fr) | 1999-03-15 | 1999-03-15 | Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant |
| FR99/03154 | 1999-03-15 | ||
| PCT/FR2000/000623 WO2000054790A1 (fr) | 1999-03-15 | 2000-03-15 | Fractions membranaires bacteriennes immunostimulantes dans le traitement de cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002539170A true JP2002539170A (ja) | 2002-11-19 |
| JP2002539170A5 JP2002539170A5 (https=) | 2007-05-10 |
Family
ID=9543185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000604865A Pending JP2002539170A (ja) | 1999-03-15 | 2000-03-15 | 癌治療における免疫刺激性の細菌膜フラクション |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7033591B1 (https=) |
| EP (1) | EP1161250B9 (https=) |
| JP (1) | JP2002539170A (https=) |
| CN (1) | CN1202127C (https=) |
| AT (1) | ATE302014T1 (https=) |
| AU (1) | AU776350B2 (https=) |
| BR (1) | BR0009052A (https=) |
| CA (1) | CA2367211A1 (https=) |
| DE (1) | DE60022011T2 (https=) |
| DK (1) | DK1161250T3 (https=) |
| ES (1) | ES2246831T3 (https=) |
| FR (1) | FR2790960B1 (https=) |
| WO (1) | WO2000054790A1 (https=) |
| ZA (1) | ZA200107368B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020536848A (ja) * | 2017-08-31 | 2020-12-17 | マクロファージ ファーマ リミテッド | Ｉｌ−１２産生の刺激による癌の治療 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2808445A1 (fr) * | 2000-05-04 | 2001-11-09 | Pf Medicament | Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues |
| FR2809014A1 (fr) * | 2000-05-16 | 2001-11-23 | Pf Medicament | Utilisation d'une proteine ompa d'enterobacterie comme agent antimicrobien |
| GB2370838A (en) * | 2001-01-06 | 2002-07-10 | Benedikt Timmerman | Immunogenic complex |
| FR2822071B1 (fr) * | 2001-03-15 | 2005-07-01 | Pf Medicament | Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques |
| EP4241853B1 (en) * | 2013-11-26 | 2026-02-11 | Zoetis Services LLC | Compositions for induction of immune response |
| CN113727722A (zh) * | 2019-02-22 | 2021-11-30 | 伊夫罗生物科学公司 | 细菌膜制剂 |
| EP4190894A1 (en) | 2021-12-03 | 2023-06-07 | CiMaas B.V. | Method for the production of mature dendritic cells in vitro using a bacterial lysate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58164514A (ja) * | 1982-03-09 | 1983-09-29 | ピエ−ル・フア−ブル・ソシエテ・アノニム | 免疫刺激性プロテオグリカンおよびその製造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2471785A1 (fr) * | 1979-12-21 | 1981-06-26 | Fabre Sa Pierre | Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn |
| FR2596064B1 (fr) * | 1986-03-18 | 1990-02-02 | Pf Medicament | Procedes industriels de fabrication de vaccins ribosomaux et vaccins ribosomaux obtenus |
| AU603585B2 (en) * | 1986-05-07 | 1990-11-22 | Sloan-Kettering Institute For Cancer Research | Vaccine for stimulating or enhancing production of antibodies directed against GM2 |
| AU7477791A (en) * | 1990-03-02 | 1991-09-18 | Joaquin J. Jimenez | Method for treating cancer using combination chemotherapy and brm |
| US5242806A (en) * | 1990-05-07 | 1993-09-07 | Baxter Diagnostics Inc. | Method for conducting the cytotoxicity assays on tumor cells |
| US5776898A (en) * | 1991-05-14 | 1998-07-07 | Dana-Farber Cancer Institute | Method for treating a tumor with a chemotherapeutic agent |
| US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| FR2726472B1 (fr) * | 1994-11-07 | 1997-01-31 | Pf Medicament | Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin |
| US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
| FR2785542B1 (fr) * | 1998-11-06 | 2001-02-09 | Pf Medicament | UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES |
-
1999
- 1999-03-15 FR FR9903154A patent/FR2790960B1/fr not_active Expired - Fee Related
-
2000
- 2000-03-15 CA CA002367211A patent/CA2367211A1/fr not_active Abandoned
- 2000-03-15 DE DE60022011T patent/DE60022011T2/de not_active Expired - Lifetime
- 2000-03-15 ES ES00910947T patent/ES2246831T3/es not_active Expired - Lifetime
- 2000-03-15 WO PCT/FR2000/000623 patent/WO2000054790A1/fr not_active Ceased
- 2000-03-15 CN CNB008050503A patent/CN1202127C/zh not_active Expired - Fee Related
- 2000-03-15 JP JP2000604865A patent/JP2002539170A/ja active Pending
- 2000-03-15 AT AT00910947T patent/ATE302014T1/de not_active IP Right Cessation
- 2000-03-15 BR BR0009052-2A patent/BR0009052A/pt not_active Application Discontinuation
- 2000-03-15 AU AU32981/00A patent/AU776350B2/en not_active Ceased
- 2000-03-15 EP EP00910947A patent/EP1161250B9/fr not_active Expired - Lifetime
- 2000-03-15 DK DK00910947T patent/DK1161250T3/da active
- 2000-03-15 US US09/936,677 patent/US7033591B1/en not_active Expired - Fee Related
-
2001
- 2001-09-06 ZA ZA2001/07368A patent/ZA200107368B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58164514A (ja) * | 1982-03-09 | 1983-09-29 | ピエ−ル・フア−ブル・ソシエテ・アノニム | 免疫刺激性プロテオグリカンおよびその製造方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020536848A (ja) * | 2017-08-31 | 2020-12-17 | マクロファージ ファーマ リミテッド | Ｉｌ−１２産生の刺激による癌の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1343125A (zh) | 2002-04-03 |
| CN1202127C (zh) | 2005-05-18 |
| AU3298100A (en) | 2000-10-04 |
| EP1161250B1 (fr) | 2005-08-17 |
| EP1161250B9 (fr) | 2006-07-05 |
| DE60022011T2 (de) | 2006-06-14 |
| FR2790960B1 (fr) | 2002-10-31 |
| DE60022011D1 (de) | 2005-09-22 |
| BR0009052A (pt) | 2001-12-26 |
| US7033591B1 (en) | 2006-04-25 |
| ATE302014T1 (de) | 2005-09-15 |
| WO2000054790A1 (fr) | 2000-09-21 |
| CA2367211A1 (fr) | 2000-09-21 |
| FR2790960A1 (fr) | 2000-09-22 |
| AU776350B2 (en) | 2004-09-02 |
| EP1161250A1 (fr) | 2001-12-12 |
| ES2246831T3 (es) | 2006-03-01 |
| ZA200107368B (en) | 2002-06-26 |
| DK1161250T3 (da) | 2005-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021189678A1 (zh) | 一种全细胞组分的输送系统及其应用 | |
| JP2024036364A (ja) | Ｉ型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物 | |
| CN112114129A (zh) | 肿瘤特异性t细胞的检测方法 | |
| US20080247989A1 (en) | Reishi - Mediated Enhancement of Human Tissue Progenitor Cell Adhesion and Differentiation | |
| WO2024250371A1 (zh) | 一种基于癌细胞和/或肿瘤组织裂解物组分和合成癌症抗原的癌症疫苗及制备方法 | |
| CN115561145B (zh) | 一种癌细胞特异性t细胞的检测方法及试剂盒 | |
| WO2024212379A1 (zh) | 一种癌细胞特异性t细胞的检测试剂盒 | |
| US6326357B1 (en) | Bacterial cell complex composition and method of use | |
| JP2002539170A (ja) | 癌治療における免疫刺激性の細菌膜フラクション | |
| Katz et al. | Regulation of accessory cell function by retinoids in murine immune responses | |
| WO2024250376A1 (zh) | 一种体外激活的含有树突状细胞和b细胞的混合细胞癌症疫苗及其应用 | |
| CN114984199A (zh) | 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用 | |
| US20040022870A1 (en) | Immunogenic TLP composition | |
| AU751667B2 (en) | Composition and method for the treatment of bladder cancer | |
| JPH0892112A (ja) | サイトカイン産生促進剤 | |
| MXPA01009343A (en) | Immunostimulant bacterial membrane fractions in cancer treatment | |
| WO2018045534A1 (zh) | 一种增强免疫功能的静脉注射剂 | |
| ZA200107628B (en) | Bacterial membrane fractions with adjuvant effect. | |
| CN118846018A (zh) | 一种可持续刺激的特异性t细胞和癌症疫苗的联合药物及其应用 | |
| CN118576624A (zh) | 一种自溶沙门氏菌-纳米胶囊输送系统、免疫刺激水凝胶及其应用 | |
| CN119587685A (zh) | 一种负载半抗原物质修饰的癌细胞和/或肿瘤组织的裂解物组分的癌症疫苗及制备方法 | |
| WO2026081304A1 (zh) | 一种抗原特异性t细胞及其制备方法和应用 | |
| AU783851B2 (en) | Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent | |
| CN121930362A (zh) | 一种猪IL-2–IFN-α–Tα1干扰素融合蛋白及其制备方法和应用 | |
| CN119060980A (zh) | CaMKII结合域自组装蛋白质纳米颗粒及其制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070312 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100622 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100921 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101021 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101028 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101122 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110419 |